| Size | Price | Stock | Qty |
|---|---|---|---|
| 1mg |
|
||
| Other Sizes |
| Targets |
Chikusetsusaponin Ib targets acetylcholinesterase (AChE), acting as a potent inhibitor. It has anti-Alzheimer's disease activity. By inhibiting AChE, it increases acetylcholine levels, enhancing cholinergic neurotransmission, which is relevant for the treatment of Alzheimer's disease.
|
|---|---|
| ln Vitro |
In cell-free enzyme assays, Chikusetsusaponin Ib inhibits AChE activity. It is a potent AChE inhibitor. Its inhibitory activity is measured using standard AChE inhibition assays, where it reduces the hydrolysis of chromogenic substrates. These assays confirm its potential for Alzheimer's disease research. Cellular assays for Chikusetsusaponin Ib are not extensively detailed. However, as an AChE inhibitor, it would be expected to increase acetylcholine levels in neuronal cell cultures. Its neuroprotective effects could be assessed in models of neurodegeneration.
|
| ln Vivo |
In vivo, Chikusetsusaponin Ib has anti-Alzheimer's disease activity. It is a natural product found in Panax species. Studies on its specific in vivo effects are limited, but it is used in research on Alzheimer's disease.
|
| Enzyme Assay |
Cell-free enzyme inhibition assays for Chikusetsusaponin Ib are performed using purified AChE enzyme. The enzyme is incubated with varying concentrations of the compound and a chromogenic substrate. The rate of substrate hydrolysis is measured spectrophotometrically, and the IC50 value is determined from the inhibition curve.
|
| Cell Assay |
Cellular assays for Chikusetsusaponin Ib could be conducted using neuronal cell lines. Cells would be treated with the compound, and markers of cholinergic function, such as acetylcholine levels, could be measured. Neuroprotective effects could be assessed in models of neurodegeneration.
|
| Animal Protocol |
In vivo studies on Chikusetsusaponin Ib are limited, as it is primarily studied as a natural product. It may be administered to animal models to study its pharmacokinetics and potential therapeutic effects in Alzheimer's disease.
|
| ADME/Pharmacokinetics |
The pharmacokinetic properties of Chikusetsusaponin Ib, as a saponin, may be characterized by poor oral bioavailability due to high molecular weight and poor membrane permeability. It is likely metabolized by gut microbiota. Detailed PK parameters are not available in the provided sources.
|
| Toxicity/Toxicokinetics |
Preclinical toxicity data for Chikusetsusaponin Ib are limited. As a natural product, it is generally considered to have low toxicity. However, comprehensive toxicological studies would be required for therapeutic development.
|
| References | |
| Additional Infomation |
Chikusetsusaponin Ib is a triterpenoid saponin that functions as a metabolite.
Chikusetsusaponin Ib is a research compound with potential applications in Alzheimer's disease research. It is a potent AChE inhibitor and a natural product found in Panax species. It is not approved for clinical use. |
| Molecular Formula |
C47H74O18
|
|---|---|
| Molecular Weight |
927.08
|
| Exact Mass |
926.488
|
| CAS # |
59252-87-8
|
| PubChem CID |
77916057
|
| Appearance |
Typically exists as solid at room temperature
|
| LogP |
0.871
|
| Hydrogen Bond Donor Count |
10
|
| Hydrogen Bond Acceptor Count |
18
|
| Rotatable Bond Count |
10
|
| Heavy Atom Count |
65
|
| Complexity |
1830
|
| Defined Atom Stereocenter Count |
0
|
| SMILES |
CC1(C)CCC2(CCC3(C)C(=CCC4C5(C)CCC(OC6OC(C(OC7OC(CO)C(O)C7O)C(O)C6O)C(=O)OC6OC(CO)C(O)C(O)C6O)C(C)(C)C5CCC34C)C2C1)C(O)=O |c:10|
|
| InChi Key |
CGEOMQZMNZQKNQ-UHFFFAOYSA-N
|
| InChi Code |
InChI=1S/C47H74O18/c1-42(2)14-16-47(41(58)59)17-15-45(6)21(22(47)18-42)8-9-26-44(5)12-11-27(43(3,4)25(44)10-13-46(26,45)7)62-40-34(56)31(53)35(63-38-32(54)29(51)24(20-49)60-38)36(64-40)37(57)65-39-33(55)30(52)28(50)23(19-48)61-39/h8,22-36,38-40,48-56H,9-20H2,1-7H3,(H,58,59)
|
| Chemical Name |
10-[5-[3,4-dihydroxy-5-(hydroxymethyl)oxolan-2-yl]oxy-3,4-dihydroxy-6-[3,4,5-trihydroxy-6-(hydroxymethyl)oxan-2-yl]oxycarbonyloxan-2-yl]oxy-2,2,6a,6b,9,9,12a-heptamethyl-1,3,4,5,6,6a,7,8,8a,10,11,12,13,14b-tetradecahydropicene-4a-carboxylic acid
|
| HS Tariff Code |
2934.99.9001
|
| Storage |
Powder -20°C 3 years 4°C 2 years In solvent -80°C 6 months -20°C 1 month |
| Shipping Condition |
Room temperature (This product is stable at ambient temperature for a few days during ordinary shipping and time spent in Customs)
|
| Solubility (In Vitro) |
May dissolve in DMSO (in most cases), if not, try other solvents such as H2O, Ethanol, or DMF with a minute amount of products to avoid loss of samples
|
|---|---|
| Solubility (In Vivo) |
Note: Listed below are some common formulations that may be used to formulate products with low water solubility (e.g. < 1 mg/mL), you may test these formulations using a minute amount of products to avoid loss of samples.
Injection Formulations
Injection Formulation 1: DMSO : Tween 80： Saline = 10 : 5 : 85 (i.e. 100 μL DMSO stock solution → 50 μL Tween 80 → 850 μL Saline)(e.g. IP/IV/IM/SC) *Preparation of saline: Dissolve 0.9 g of sodium chloride in 100 mL ddH ₂ O to obtain a clear solution. Injection Formulation 2: DMSO : PEG300 ：Tween 80 : Saline = 10 : 40 : 5 : 45 (i.e. 100 μL DMSO → 400 μLPEG300 → 50 μL Tween 80 → 450 μL Saline) Injection Formulation 3: DMSO : Corn oil = 10 : 90 (i.e. 100 μL DMSO → 900 μL Corn oil) Example: Take the Injection Formulation 3 (DMSO : Corn oil = 10 : 90) as an example, if 1 mL of 2.5 mg/mL working solution is to be prepared, you can take 100 μL 25 mg/mL DMSO stock solution and add to 900 μL corn oil, mix well to obtain a clear or suspension solution (2.5 mg/mL, ready for use in animals). View More
Injection Formulation 4: DMSO : 20% SBE-β-CD in saline = 10 : 90 [i.e. 100 μL DMSO → 900 μL (20% SBE-β-CD in saline)] Oral Formulations
Oral Formulation 1: Suspend in 0.5% CMC Na (carboxymethylcellulose sodium) Oral Formulation 2: Suspend in 0.5% Carboxymethyl cellulose Example: Take the Oral Formulation 1 (Suspend in 0.5% CMC Na) as an example, if 100 mL of 2.5 mg/mL working solution is to be prepared, you can first prepare 0.5% CMC Na solution by measuring 0.5 g CMC Na and dissolve it in 100 mL ddH2O to obtain a clear solution; then add 250 mg of the product to 100 mL 0.5% CMC Na solution, to make the suspension solution (2.5 mg/mL, ready for use in animals). View More
Oral Formulation 3: Dissolved in PEG400 (Please use freshly prepared in vivo formulations for optimal results.) |
| Preparing Stock Solutions | 1 mg | 5 mg | 10 mg | |
| 1 mM | 1.0787 mL | 5.3933 mL | 10.7866 mL | |
| 5 mM | 0.2157 mL | 1.0787 mL | 2.1573 mL | |
| 10 mM | 0.1079 mL | 0.5393 mL | 1.0787 mL |
*Note: Please select an appropriate solvent for the preparation of stock solution based on your experiment needs. For most products, DMSO can be used for preparing stock solutions (e.g. 5 mM, 10 mM, or 20 mM concentration); some products with high aqueous solubility may be dissolved in water directly. Solubility information is available at the above Solubility Data section. Once the stock solution is prepared, aliquot it to routine usage volumes and store at -20°C or -80°C. Avoid repeated freeze and thaw cycles.
Calculation results
Working concentration： mg/mL；
Method for preparing DMSO stock solution： mg drug pre-dissolved in μL DMSO (stock solution concentration mg/mL). Please contact us first if the concentration exceeds the DMSO solubility of the batch of drug.
Method for preparing in vivo formulation:：Take μL DMSO stock solution, next add μL PEG300, mix and clarify, next addμL Tween 80, mix and clarify, next add μL ddH2O，mix and clarify.
(1) Please be sure that the solution is clear before the addition of next solvent. Dissolution methods like vortex, ultrasound or warming and heat may be used to aid dissolving.
(2) Be sure to add the solvent(s) in order.
Products are for research use only; We do not sell to patients
Copyright 2020 InvivoChem LLC | All Rights Reserved
